Next Article in Journal
Automatic Identification of Myeloperoxidase Natural Inhibitors in Plant Extracts
Next Article in Special Issue
Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity
Previous Article in Journal
The Production and Evaluation of an Electrochemical Sensors for Strychnine and Its Main Metabolite Strychnine N-Oxide for Their Use in Biological Samples
Previous Article in Special Issue
Designing Novel Compounds for the Treatment and Management of RET-Positive Non-Small Cell Lung Cancer—Fragment Based Drug Design Strategy
 
 

Order Article Reprints

Journal: Molecules, 2022
Volume: 27
Number: 1827

Article: Synthesis, Characterization, and Assessment of Anti-Cancer Potential of ZnO Nanoparticles in an In Vitro Model of Breast Cancer
Authors: by Alaa A. A. Aljabali, Mohammad A. Obeid, Hamid A. Bakshi, Walhan Alshaer, Raed M. Ennab, Bahaa Al-Trad, Wesam Al Khateeb, Khalid M. Al-Batayneh, Abdulfattah Al-Kadash, Shrouq Alsotari, Hamdi Nsairat and Murtaza M. Tambuwala
Link: https://www.mdpi.com/1420-3049/27/6/1827

MDPI provides article reprints in high quality with convenient shipping to destinations worldwide. The articles are printed in on premium paper with high-resolution figures. Our covers are customized to your article and designed to be complimentary to the journal. These reprints are ideal additions to your portfolio. Copy details: 135g/m2 paper, 2x stitched, full colour and glossy finish, orderable in quantities from 10 to 1000.

If you have any questions, or special requests, please write to our support team; we are happy to provide you with the information you need.

Reprint Options

If you need more than 400 copies, please contact us by e-mail (publisher@mdpi.com) and we will prepare an individual offer for you.

Order Cost and Details

Contact Person

Invoice Address

Notes or Comments

Validate and Place Order

The order must be prepaid after it is placed

req denotes required fields.
Back to TopTop